Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda to Set Up Japan Oncology, Vaccine Business Units as Part of Corporate Reorganization
March 24, 2015
- Merck KGaA Gauging Regional Priorities for PD-L1 Inhibitor Development: Exec
March 24, 2015
- Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
- Pfizer Japan Voluntarily Recalls Generic Gemcitabine
March 23, 2015
- Opicapone Reduces Off-Time by 2 Hours in Parkinson’s Disease Patients as Add-On to Levodopa: Ono
March 20, 2015
- Daiichi Sankyo, AZ to Copromote Constipation Treatment Movantik in US
March 20, 2015
- Astellas Files Kiklin to Treat Non-Dialysis CKD Patients
March 18, 2015
- MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
- Alirocumab Meets Primary Efficacy Endpoint in PIII Study: Sanofi
March 17, 2015
- Minophagen Seeks Approval for CTCL Treatment
March 17, 2015
- Selexipag Lowers Risk of Morbidity, Mortality Events by 40% in PIII Study
March 17, 2015
- AnGes MG Initiates PIII Study of Nucleotide NF-κB Decoy Oligo for Atopic Dermatitis
March 17, 2015
- ViiV Receives Approval for HIV Infection Treatment Triumeq
March 17, 2015
- Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
- Meiji Seika Halts Development of Antiallergic Treatment, Terminating Pact with Amalyte
March 16, 2015
- Eisai Revises Deal with Epizyme on Cancer Therapies
March 13, 2015
- Santen Earns Approval for Preservative-Free Glaucoma Eye Drops
March 13, 2015
- Sanwa Kagaku Names Hata as Successor to Late President Yamamoto
March 13, 2015
- AZ Appoints BMKK’s Taniguchi as Head of R&D
March 13, 2015
- AZ Receives Approval for Bydureon Pen Formulation
March 13, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…